title: Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia.
abstract: The persistence of abnormal coagulation test results after standard treatment with fresh frozen plasma (FFP) poses significant problems in children with acute leukemia requiring a diagnostic lumbar puncture and intrathecal chemotherapy. We report the prophylactic use of a single dose of 90 microg/kg recombinant activated factor VII (rFVIIa) in three children and the rapid correction of abnormal coagulation test results previously not corrected by FFP. Administration of rFVIIa was useful in avoiding a delay of diagnostic lumbar punctures and intrathecal chemotherapy. Hemorrhagic complications and adverse effects of rFVIIa were not observed. Prospective evaluation of this indication and dose appears warranted. (c) 2005 Wiley-Liss, Inc.
authors: The Hospital for Sick Children, Division of Hematology/Oncology, Department of Pediatrics, University of Toronto, Toronto, Ontario M5G1X8, Canada.
authors: Prabodh
authors: P
authors: Das
authors: Manuel
authors: M
authors: Carcao
authors: Johann
authors: J
authors: Hitzler
mesh_terms: D000293:Adolescent; D001778:Blood Coagulation Disorders / Q000209:etiology / Q000628:therapy*; D002648:Child; D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000150:complications*; D008297:Male; D011292:Premedication; D011994:Recombinant Proteins / Q000627:therapeutic use; D013129:Spinal Puncture / Q000009:adverse effects*
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa